Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine

13. oktober 2014 oppdatert av: Boehringer Ingelheim

The Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine (an Open-label, Randomised, Single-dose, Two-way Crossover Study)

Study to investigate the effect of cytochrome P 450 3A4 inhibition by itraconazole on the single dose pharmacokinetics of cilobradine

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

25

Fase

  • Fase 1

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

21 år til 55 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Mann

Beskrivelse

Inclusion Criteria:

  1. Healthy males according to the following criteria:

    Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests

    1.1 No finding deviating from normal and of clinical relevance

    1.2 No evidence of a clinically relevant concomitant disease

  2. Age ≥21 and Age ≤55 years
  3. BMI ≥18.5 and BMI < 30 kg/m2 (Body Mass Index)
  4. Resting pulse rate (PR; after 10 min. in the supine position) of more than 55 bpm
  5. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation

Exclusion Criteria:

  1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, ophthalmological, or hormonal disorders
  2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  3. History of relevant orthostatic hypotension, fainting spells or blackouts.
  4. Chronic or relevant acute infections
  5. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  6. Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  7. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial.
  8. Participation in another trial with an investigational drug within two months prior to administration or during the trial
  9. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)
  10. Inability to refrain from smoking on trial days
  11. Alcohol abuse (more than 60 g/day)
  12. Drug abuse
  13. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  14. Excessive physical activities (within one week prior to administration or during the trial)
  15. Any laboratory value outside the reference range that is of clinical relevance

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Cilobradine, low dose plus itraconazole
Pre-study
Andre navn:
  • Sempera®
Aktiv komparator: Cilobradine, low dose
Pre-study
Eksperimentell: Cilobradine, high dose plus itraconazole
main study
Andre navn:
  • Sempera®
Aktiv komparator: Cilobradine, high dose
main study

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Tidsramme: up to 56 hours after administration of Cilobradine
up to 56 hours after administration of Cilobradine
Maximum measured concentration of the analyte in plasma (Cmax)
Tidsramme: up to 56 hours after administration of Cilobradine
up to 56 hours after administration of Cilobradine

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)
Tidsramme: up to 56 hours after administration of Cilobradine
up to 56 hours after administration of Cilobradine
Time from dosing to Cmax (Tmax)
Tidsramme: up to 56 hours after administration of Cilobradine
up to 56 hours after administration of Cilobradine
Terminal rate constant in plasma (λz)
Tidsramme: up to 56 hours after administration of Cilobradine
up to 56 hours after administration of Cilobradine
Terminal half-life of the analyte in plasma (t1/2)
Tidsramme: up to 56 hours after administration of Cilobradine
up to 56 hours after administration of Cilobradine
Mean residence time of the analyte in the body after p.o. administration (MRTpo)
Tidsramme: up to 56 hours after administration of Cilobradine
up to 56 hours after administration of Cilobradine
Apparent clearance of the analyte in the plasma after extravascular administration (CL/F)
Tidsramme: up to 56 hours after administration of Cilobradine
up to 56 hours after administration of Cilobradine
Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)
Tidsramme: up to 56 hours after administration of Cilobradine
up to 56 hours after administration of Cilobradine
Amount of parent compound excreted in urine with zero to 72 h in % of dose (fe0-tz)
Tidsramme: up to 72 hours after administration of Cilobradine
up to 72 hours after administration of Cilobradine
Renal clearance of cilobradine (CLR,0-tz)
Tidsramme: up to 72 hours after administration of Cilobradine
up to 72 hours after administration of Cilobradine
Number of subjects with adverse events
Tidsramme: up to 46 days
up to 46 days
Occurrence of visual phenomena
Tidsramme: up to 46 days
questionnaire
up to 46 days
Number of subjects with clinically relevant findings in vital signs
Tidsramme: up to 32 days
blood pressure, pulse rate
up to 32 days
Number of subjects with clinically relevant findings in laboratory tests
Tidsramme: up to 32 days
up to 32 days
Number of subjects with clinically relevant findings in 12-lead electrocardiogram
Tidsramme: up to 32 days
up to 32 days
Assessment of tolerability by investigator on a 4-point scale
Tidsramme: within 8 days after last PK sampling
within 8 days after last PK sampling

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. januar 2004

Primær fullføring (Faktiske)

1. april 2004

Datoer for studieregistrering

Først innsendt

13. oktober 2014

Først innsendt som oppfylte QC-kriteriene

13. oktober 2014

Først lagt ut (Anslag)

15. oktober 2014

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

15. oktober 2014

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. oktober 2014

Sist bekreftet

1. oktober 2014

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere